摘要
目的分析采用达格列净+双歧杆菌四联活菌片对超重及肥胖2型糖尿病进行治疗的临床效果及价值。方法选取2021年1—12月在该院接受治疗的126例超重及肥胖2型糖尿病患者,以用药方案的差异性分组,其中63例纳入常规用药组,在常规治疗基础上接受达格列净片治疗,63例纳入联合用药组,在常规治疗基础上接受达格列净+双歧杆菌四联活菌片治疗。对比两组患者治疗前及治疗24周时的血糖水平FPG、2 hPG及血脂水平(TC、TG)。结果两组患者治疗前的血糖水平对比,差异无统计学意义(P>0.05);治疗24周时,联合用药组患者的FPG、2 hPG、TC、TG均明显低于常规用药组,差异有统计学意义(P<0.05)。结论采用达格列净联合双歧杆菌四联活菌片对超重及肥胖2型糖尿病患者进行治疗能够有效改善患者的血脂及血糖情况,有利于患者控制自身病情的发展,将各项指标控制在较为理想的状态。
Objective To analyze the clinical effect and value of dapagliflozin+bifidobacterium quadruple viable tablet in the treatment of overweight and obese type 2 diabetes mellitus.Methods 126 overweight and obese patients with type 2 diabetes who were treated in the hospital from January to December 2021 were selected and divided into groups according to the differences of medication schemes,of which 63 cases were included in the routine medication group,receiving dagglitazone tablets on the basis of routine treatment,and 63 cases were included in the combined medication group,receiving dagglitazone+Bifidobacterium tetralogy live tablets on the basis of routine treatment.The blood glucose levels FPG,2 hPG and blood lipid levels(TC and TG)were compared between the two groups before treatment and at 24 weeks of treatment.Results There was no statistically significant difference in blood glucose levels between the two groups before treatment(P>0.05).At 24 weeks of treatment,the FPG,2 hPG,TC,and TG of the patients in the combination drug group were significantly lower than those in the routine drug group,the difference was statistically significant(P<0.05).Conclusion The use of dapagliflozin combined with Bifidobacterium quadruple viable bacteria tablets in the treatment of overweight and obese patients with type 2 diabetes can effectively improve the blood lipids and blood glucose of the patients.It is beneficial for patients to control the development of their own disease and control the indicators in a relatively ideal state.
作者
王超俊
赵增政
WANG Chaojun;ZHAO Zengzheng(Department of Pharmacy,Juxian People's Hospital,Rizhao,Shandong Province,276500 China)
出处
《糖尿病新世界》
2022年第12期113-115,119,共4页
Diabetes New World Magazine
关键词
达格列净
双歧杆菌四联活菌片
超重
肥胖2型糖尿病
Dapagliflozin
Bifidobacteria quadruple viable tablet
Overweight
Obesity type 2 diabetes mellitus